Stelara 90 MG/ML syringeml
Ended Awarded
- Contract number
- SPE2DR26FCEZ2
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $16,584
Award facts
- Contract value 100% obligated
- $16,584.13 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $16,584.13 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Stelara 90 mg/ml syringes. This firm fixed-price delivery order, issued on November 13, 2025, with an ultimate completion date of December 5, 2025, operates under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the Defense Logistics Agency. The delivery order contains no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. DMS Pharmaceutical Group has been registered in the System for Award Management since 2001 and maintains a critical role in the federal pharmaceutical supply chain serving Department of Defense healthcare operations.
This delivery order is issued under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion Defense Logistics Agency acquisition strategy designed to provide comprehensive pharmaceutical support to military healthcare facilities worldwide. DMS Pharmaceutical Group's parent Indefinite Delivery Contract under this program, designated SPE2DR, carries a ceiling value of $499.999 billion and extends through December 31, 2036, with a 30-month base period followed by three 30-month option periods. The company's product portfolio encompasses branded and generic prescription medications, biologics, vaccines, specialty pharmaceuticals, and medical consumables, positioning it as a regional prime vendor contractor capable of fulfilling the diverse pharmaceutical requirements of the Department of Defense's military medical system.
Quick answers
Who was awarded contract SPE2DR26FCEZ2?
SPE2DR26FCEZ2 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on November 13, 2025.
How much is contract SPE2DR26FCEZ2 worth?
The government has obligated $16,584 on SPE2DR26FCEZ2.
Is contract SPE2DR26FCEZ2 an order under another contract?
Yes. SPE2DR26FCEZ2 is a delivery order under SPE2DR25D9130, an indefinite delivery contract.
Was contract SPE2DR26FCEZ2 competed?
The extent of competition for SPE2DR26FCEZ2 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award